Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study

被引：0
|
作者：
Pasello, G. [1 ,2 ]
Lorenzi, M. [1 ,2 ]
Crivellaro, G. [3 ]
Capelletto, E. [4 ]
Buttice, S. [4 ]
Perrone, F. [5 ]
Tiseo, M. [5 ,6 ]
Scotti, V. [7 ]
Polo, V. [8 ]
Favaretto, A.
Montrone, M. [9 ]
Berardi, R. [10 ]
Zustovich, F. [11 ]
Toschi, L. [12 ]
Bearz, A. [13 ]
Milella, M. [14 ]
Frega, S.
Bonanno, L. [3 ]
Guarneri, V. [1 ,2 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] IOV Ist Oncol Veneto IRCCS, Padua, Italy
[3] IOV Ist Oncol Veneto IRCCS, Oncol 2, Padua, Italy
[4] Azienda Osped Univ San Luigi Gonzaga, Dept Oncol, Orbassano, Italy
[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[6] Univ Parma, Dept Med & Surg, Parma, Italy
[7] AOUC Azienda Osped Univ Careggi, Dipartimento Oncol, Florence, Italy
[8] Osped Reg Ca Foncello, AULSS2 Dept Med Specialist, Treviso, Italy
[9] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Dipartimento Area Med, Bari, Italy
[10] AOU Osped Riuniti Umberto 1 GM Lancisi G Salesi, Dept Internal Med, Clin Oncol, Torrette Di Ancona, Italy
[11] Osped Belluno, Belluno, Italy
[12] Ist Clin Humanitas, Med Oncol Dept, Rozzano, Italy
[13] Ctr Riferimento Oncol CRO, Med Oncol, Aviano, Italy
[14] Univ Verona, Med Oncol 1, Fac Med, Verona, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
    Trummer, Arne
    Bethge, Andre
    Dickgreber, Nicolas
    Dittrich, Ina
    Golpon, Heiko
    Hoffknecht, Petra
    Overbeck, Tobias R.
    Wesseler, Claas
    Reck, Martin
    LUNG CANCER, 2022, 174 : 141 - 145
  • [2] NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
    Trummer, Arne Rainer
    Bethge, Andre
    Dickgreber, Nicolas J.
    Dittrich, Ina
    Golpon, Heiko
    Hoffknecht, Petra
    Overbeck, Tobias R.
    Wesseler, Claas
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor
    Yamada, Tomoharu
    Minami, Tatsuya
    Tateishi, Ryosuke
    Koike, Kazuhiko
    LIVER INTERNATIONAL, 2021, 41 (09) : 2233 - 2234
  • [4] Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
    Liao, Bin-Chi
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1426 - 1428
  • [5] Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
    Bridges, J.
    De La Cruz, M.
    Pavilack, M.
    Flood, E.
    Janssen, E.
    Chehab, N.
    Fernandes, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S343 - S343
  • [6] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [7] Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
    Fu, S.
    Liu, J.
    Fu, P.
    Li, H.
    Yang, X.
    Xie, C.
    Zhang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S414 - S415
  • [8] Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
    Neal, J. W.
    Lim, F. L.
    Aix, S. P.
    Viteri, S.
    Santoro, A.
    Spencer, K.
    Fang, B.
    Khrizman, P.
    Kim, J.
    Subbiah, V.
    Sudhagoni, R.
    Samaraweera, L.
    Andrianova, L.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S439 - S439
  • [9] Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial
    Kim, H.
    Park, S.
    Kim, T. M.
    Han, J-Y.
    Lee, G-W.
    Shim, B. Y.
    Lee, Y-G.
    Kim, S-W.
    Ock, C-Y.
    Hwang, S.
    Lee, Y.
    Kim, R.
    Jung, H. A.
    Sun, J-M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1636 - S1636
  • [10] Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard, Nicolas
    FUTURE ONCOLOGY, 2018, 14 (11) : 1117 - 1132
12345